Biotron : 13 Jan 2017Biotron Limited Presents at Biotech Showcase 2017

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: [phone] Fax: [phone]

E-mail: [e-mail] Website: www.biotron.com.au

13 January 2017

The Manager Companies ASX Limited

20 Bridge Street

Sydney NSW 2000 (22 pages by email)

Dear Madam

BIOTRON LIMITED PRESENTS AT BIOTECH SHOWCASETM 2017

Biotron Limited advises that Dr Michelle Miller, Managing Director, will be giving the attached presentation to the Biotech ShowcaseTM 2017 Conference being held this week in San Francisco, California, USA.

In addition, Dr Miller will give briefings to USA institutional investors and pharmaceutical company representatives as part of activities surrounding the annual JP Morgan Healthcare Conference. This is one of the most important annual healthcare investor conferences, attracting thousands of healthcare and life science business executives, as well as investors and analysts, to San Francisco.

The Biotech ShowcaseTM features corporate presentations by innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaborations. Now in its ninth year, it expects to attract upwards of 2,800 attendees.

Yours sincerely

Peter J. Nightingale Company Secretary

pjn8740

BIOTRON LIMITED (ASX:BIT) Update - January 2017

Forward Looking Statements

This presenta,on may contain forward-looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec,ves of its management. These statements are statements that are not historical facts. Words such as "should", "expects", "an,cipates", "es,mates", "believes" or similar expressions, as they relate to Biotron Limited, are intended to iden,fy forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron's current expecta,ons and assump,ons as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assump,ons or expecta,ons could cause actual results to differ materially from current expecta,ons.

Biotron Limited

• Spun out from John Cur,n School of Medical Research at the Australian Na,onal University in 1999

• Listed on ASX in Jan 2001 (ASX:BIT)

• Headquartered in Sydney, Australia

• Directors

  • Michael Hoy Chairman

  • Michelle Miller CEO & Managing Director; ex-Johnson & Johnson Research; ex-Start-up Australia biotech fund

  • Denis Wade Independent non-execu,ve director; ex-J&J (Chairman and MD Johnson & Johnson Research); Director of Heartware Inc (NASDAQ:HTWR)

  • Susan Pond Independent non-execu,ve director; ex-J&J (Chairman and MD Johnson & Johnson Research)

  • Rob Thomas Independent non-execu,ve director; Director of Heartware Inc (NASDAQ:HTWR); Starpharma (ASX:SPL), REVA Medical Limited (ASX:RVA); Virgin Australia Limited (ASX:VAH)

Slide 2